GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SMO Clinplus Co Ltd (SZSE:301257) » Definitions » Intangible Assets

SMO Clinplus Co (SZSE:301257) Intangible Assets : ¥2.6 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is SMO Clinplus Co Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. SMO Clinplus Co's intangible assets for the quarter that ended in Mar. 2024 was ¥2.6 Mil.


SMO Clinplus Co Intangible Assets Historical Data

The historical data trend for SMO Clinplus Co's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMO Clinplus Co Intangible Assets Chart

SMO Clinplus Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intangible Assets
Get a 7-Day Free Trial 0.15 0.11 0.06 0.72 2.78

SMO Clinplus Co Quarterly Data
Dec17 Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 1.57 1.93 2.78 2.63

SMO Clinplus Co Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


SMO Clinplus Co  (SZSE:301257) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


SMO Clinplus Co Intangible Assets Related Terms

Thank you for viewing the detailed overview of SMO Clinplus Co's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


SMO Clinplus Co (SZSE:301257) Business Description

Traded in Other Exchanges
N/A
Address
No. 105 Sinan Road, Room 108, Building 1, Huangpu District, Shanghai, CHN, 200001
SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.
Executives
Lai Chun Bao Director
Ma Lin Director

SMO Clinplus Co (SZSE:301257) Headlines

No Headlines